Jacqueline Claudia Barrientos, MD
Chronic lymphocytic leukemia (CLL) is entering a new age of combination therapy, according to Jacqueline C. Barrientos, MD.
, Barrientos, an associate professor at the Feinstein Institute for Medical Research at Northwell Health, discussed these combinations trials, as well as emerging agents in the CLL pipeline.
OncLive: Can you discuss the impact of recent combination trials in CLL?
We are trying to get deeper responses than what we have seen with regular use of a B-cell receptor signaling agent. Moving forward, data such as from the TAP CLARITY trial presented by the UK group during the 2017 ASH Annual Meeting, is going to be very important. This trial evaluated ibrutinib in combination with venetoclax in patients with relapsed/refractory CLL. There was no increase in toxicity with the combination, while achieving deep responses. The MRD negativity in the patients who had more than 6 cycles was unbelievable, and many of the patients showed no evidence of disease in the peripheral blood or in the bone marrow. Additionally, many of them achieved complete remission, which is unheard of in patients taking ibrutinib as monotherapy.
... to read the full story